Point-of-care testing (POCT) — also called near-patient testing, bedside testing, or point-of-care (POC) testing — is diagnostic or monitoring testing performed at or near the site where a patient or subject is located, with a result available in time to inform an immediate decision, rather than sending a specimen to a central laboratory and waiting for a batched result. The defining feature is not the device itself but the location and timing of the test relative to the result’s use: the same analyte can be measured by a point-of-care method at a patient’s bedside or by an identical or related method on a large analyzer in a central lab, and only the former is point-of-care testing.
POCT sits at the intersection of clinical laboratory science, device management, and regulatory compliance, which is why it shows up in three very different contexts: hospitals and clinics running rapid tests at the bedside, research and clinical-trial sites screening or monitoring participants without a central lab turnaround, and procurement/compliance teams deciding which testing platforms a facility is allowed to operate under its CLIA certificate. This guide covers what qualifies as POCT, common examples, how it compares to central laboratory testing, the regulatory framework that governs it in the US, and what a defensible POCT quality program actually requires.
What Counts as Point-of-Care Testing
A test qualifies as point-of-care testing when it meets three conditions together:
- Location. The test is performed at or near the patient/subject — a hospital ward, emergency department, outpatient clinic, ambulance, pharmacy, research clinic visit, or even a patient’s home — rather than in a centralized laboratory the specimen is transported to.
- Turnaround. The result is available quickly enough (typically minutes) to inform a decision made during that same encounter: whether to admit a patient, adjust a medication dose, escalate care, or determine trial eligibility on the spot.
- Operator. The test is commonly performed by non-laboratory personnel — nurses, physicians, medical assistants, paramedics, or trained research staff — using a device designed for simplified operation, rather than by certified medical laboratory scientists running batch analyzers.
A test performed on a rapid, simplified device but sent to and run inside a central lab by lab staff (for example, a lab’s own “stat” chemistry analyzer) is not POCT in the operational sense used by CLIA and accreditation bodies — the regulatory and quality obligations that attach specifically to point-of-care testing follow the decentralized, non-laboratory-operator model, not just the speed of the assay.
Point-of-Care Testing Examples
The point-of-care testing category spans a wide range of analytes and specimen types. Commonly cited examples include:
- Blood glucose meters — the highest-volume POCT application by far, used continuously in inpatient and outpatient diabetes management.
- Rapid infectious-disease antigen tests — rapid strep, influenza, RSV, and COVID-19 antigen tests.
- Urine pregnancy tests (hCG).
- Coagulation testing (INR/PT) — used to monitor patients on warfarin or similar anticoagulants without sending a sample to central hematology.
- Blood gas and electrolyte analyzers — common in emergency departments, ICUs, and operating rooms where turnaround time directly affects care decisions.
- Cardiac troponin and B-type natriuretic peptide (BNP) assays — used to triage suspected cardiac events in emergency settings.
- Hemoglobin A1c (HbA1c) testing — used at the point of a diabetes-management visit rather than waiting for a lab result.
- Urinalysis dipsticks and fecal occult blood tests.
- Lipid panels and total cholesterol testing at community screening events or clinic visits.
Most of these are also examples of CLIA-waived testing (see below) — the two categories overlap heavily but are not identical: a test can be point-of-care without being CLIA-waived (some POC coagulation and blood gas platforms are moderate complexity), and a test can be CLIA-waived without typically being run at the point of care.
Point-of-Care Testing vs. Laboratory Testing
| Dimension | Point-of-Care Testing | Central Laboratory Testing |
|---|---|---|
| Where it happens | At or near the patient (bedside, clinic, field site) | In a dedicated clinical laboratory |
| Typical operator | Nurses, physicians, medical assistants, trained research staff | Certified medical laboratory scientists/technologists |
| Turnaround time | Minutes | Often hours, depending on batching and transport |
| Instrument scale | Small, single- or few-sample handheld or benchtop devices | High-throughput automated analyzers processing large batches |
| Typical FDA complexity | Usually waived; some moderate complexity | Spans waived through high complexity |
| Primary trade-off | Speed and convenience, at some cost to throughput, connectivity, and (for some assays) precision compared with reference methods | Higher analytical rigor and throughput, at the cost of turnaround time |
| Quality oversight model | Distributed — requires operator competency assessment across many testing sites | Centralized — a single accredited lab, single quality system |
Neither model replaces the other; most health systems and clinical research operations run both, using POCT for time-sensitive decisions and central lab testing for anything requiring higher analytical complexity, confirmatory testing, or tests without an available point-of-care platform.
The Regulatory Framework: CLIA and Point-of-Care Testing
In the US, point-of-care testing on human specimens falls under the same Clinical Laboratory Improvement Amendments (CLIA) framework, codified at 42 CFR Part 493, that governs all clinical laboratory testing — POCT does not get a separate regulatory track, but it does map disproportionately onto one part of that framework. CMS administers CLIA certification, and the FDA assigns each individual test system — not each testing location — a complexity category of waived, moderate, or high.
- Certificate of Waiver. Because most POCT devices are simple, FDA-cleared “waived” methodologies (glucose meters, rapid antigen tests, urine hCG tests), a facility running only waived tests can operate under the least burdensome CLIA certificate — no routine on-site inspection, though the facility must still follow manufacturer instructions and maintain quality practices.
- Certificate for Provider-Performed Microscopy (PPM). Covers a narrow list of moderate-complexity microscopy procedures a physician or midlevel practitioner performs personally during a patient visit — itself a form of point-of-care testing.
- Moderate-complexity POCT. Some point-of-care coagulation, blood gas, and hematology platforms are categorized moderate complexity, which brings a heavier quality-control, personnel-qualification, and proficiency-testing burden than waived testing, even though the device is still operated at the bedside.
Whether a testing site holding a Certificate of Waiver still needs a documented POCT quality program is a common point of confusion: CLIA’s on-site survey exemption for waived testing does not remove the underlying expectation that manufacturer instructions, basic quality control, and operator training are actually followed — it only removes routine CMS inspection as the enforcement mechanism, shifting the burden onto the facility’s own oversight structure.
Research and clinical-trial settings should also confirm scope before assuming a research exemption covers their point-of-care activity: under 42 CFR 493.3, CLIA does not apply to research laboratories that do not report patient-specific results for diagnosis, treatment, or health assessment — but a point-of-care test used to determine trial-participant eligibility, dosing, or safety monitoring is functioning clinically for that purpose and is generally expected to be performed under CLIA (or equivalent), independent of the study’s research status. See the CLIA certification guide for the full scope analysis.
Advantages of Point-of-Care Testing
- Faster clinical decisions. Eliminating specimen transport and batch processing can turn a multi-hour laboratory turnaround into a result available within the same patient encounter.
- Decentralized access. Testing can happen anywhere a trained operator and device are present — ambulances, rural clinics, field research sites, or a patient’s home — without requiring proximity to a central lab.
- Reduced specimen handling. Fewer transport and processing steps reduce some categories of pre-analytical error (mislabeling, degradation in transit, hemolysis from transport).
- Simplified operation. Devices are designed for use by non-laboratory-trained staff, which extends testing capability to more points of care.
Limitations of Point-of-Care Testing
- Distributed quality control burden. Instead of one lab maintaining one quality system, a POCT program has to maintain consistent competency, calibration, and QC practice across every operator and testing location — the single largest practical challenge in running a POCT program at scale.
- Narrower test menu. Most POCT platforms run a small number of analytes per device; anything outside that menu still needs central-lab testing.
- Documentation and connectivity gaps. Results generated at the bedside have to be reliably captured in the patient or research record; devices not connected to a laboratory information system or EHR create a manual documentation burden and an error opportunity central lab results don’t have to the same degree.
- Analytical trade-offs. Some point-of-care methods have wider acceptable error ranges than their central-lab reference method equivalents, which is why certain point-of-care results (e.g., a critical glucose or troponin value) are protocol-driven to trigger confirmatory central-lab testing rather than being treated as final.
Point-of-Care Testing Policy and Procedure Essentials
A defensible POCT program — whether in a clinical, research, or clinical-trial setting — is built around a written policy and procedure covering, at minimum:
- Scope and authorization. Which tests are approved for point-of-care use, at which locations, and under which CLIA certificate.
- Operator training and competency assessment. Initial and periodic (commonly annual) competency documentation for every individual operator, not just a facility-level sign-off — this is typically the single most heavily surveyed element of a POCT program.
- Quality control schedule. Manufacturer-specified QC frequency and acceptable-range documentation, including corrective action steps when QC fails.
- Proficiency testing (for non-waived tests). Enrollment and documented performance in an approved proficiency-testing program for any moderate-complexity point-of-care test.
- Result documentation and reporting. How a result reaches the patient record or research dataset, including any manual-entry verification step for devices without direct system connectivity.
- Device maintenance and lot management. Calibration verification, reagent/strip lot tracking, and expiration monitoring across every device and testing location.
Most hospitals and health systems centralize this oversight in a POCT coordinator role or committee reporting to the laboratory or pathology department, precisely because the quality burden of POCT is distributed across many operators and locations in a way central lab testing is not.
Frequently Asked Questions
What is point-of-care testing (POCT)?
Point-of-care testing is diagnostic or monitoring testing performed at or near the patient, by a non-laboratory operator, with a result available quickly enough to inform an immediate decision — rather than sending a specimen to a central laboratory for batch processing.
What are some examples of point-of-care testing?
Blood glucose meters, rapid strep/flu/COVID-19 antigen tests, urine pregnancy tests, INR/coagulation monitors, blood gas and electrolyte analyzers, cardiac troponin assays, HbA1c testing, and urinalysis dipsticks are among the most common examples.
What is a POCT blood test?
A POCT blood test is any blood-based test performed at the point of care rather than in a central laboratory — glucose, INR, blood gas, troponin, and HbA1c testing are the most common blood-based POCT examples.
How does point-of-care testing differ from laboratory testing?
POCT is performed near the patient by non-laboratory staff with results in minutes, while laboratory testing is performed by certified laboratory personnel in a centralized facility, typically with longer turnaround but broader test menus and, for many analytes, higher analytical throughput and precision.
What are the advantages of point-of-care testing?
Faster results that inform same-encounter decisions, decentralized access to testing, reduced specimen-transport handling, and simplified operation by non-laboratory staff are the main advantages, traded off against a smaller test menu and a distributed quality-control burden.
Is point-of-care testing CLIA-waived?
Most, but not all. The majority of point-of-care devices use FDA-cleared “waived” methodologies, but some point-of-care coagulation, blood gas, and hematology platforms are categorized moderate complexity and carry a heavier CLIA quality and personnel burden despite being run at the bedside.
What should a point-of-care testing policy and procedure include?
At minimum: which tests are authorized and where, operator training and competency documentation, a quality-control schedule with corrective-action steps, proficiency testing enrollment for non-waived tests, a defined result-documentation pathway, and device/reagent maintenance and lot tracking.
